A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Status:
Recruiting
Trial end date:
2028-11-24
Target enrollment:
Participant gender:
Summary
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator
selected TKI for the treatment of newly diagnosed, previously untreated patients with Ph+
CML-CP. The Investigator selected TKI will be one of the following treatment options for
first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100
mg QD or bosutinib 400 mg QD.